aTYR PHARMA (ATYR) Total Current Liabilities (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Total Current Liabilities came in at $11.7 million in Q1 2026, up 9.51% YoY from $10.7 million in Q1 2025, and down 22.77% on a QoQ basis from $15.1 million in Q4 2025.
aTYR PHARMA (ATYR) Total Current Liabilities (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Total Current Liabilities data on file, last reported at $11.7 million in Q1 2026.
- Quarterly Total Current Liabilities rose 9.51% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 9.51% YoY) and the FY2025 annual result came in at $15.1 million, up 1.21% from the prior year.
- Total Current Liabilities retreated to $11.7 million in Q1 2026, from $15.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $16.4 million in Q4 2023 to a low of $6.3 million in Q1 2022.
- A 5-year average of $13.0 million and a median of $13.7 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 130.53% — and 2025, when it tumbled 33.14%.
- Tracing ATYR's Total Current Liabilities over 5 years: stood at $13.9 million in 2022, then climbed by 18.42% to $16.4 million in 2023, then retreated by 8.83% to $15.0 million in 2024, then advanced by 1.21% to $15.1 million in 2025, then slipped by 22.77% to $11.7 million in 2026.
- The last three Total Current Liabilities figures came in at $11.7 million (Q1 2026), $15.1 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 11.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.40 Mn |
| Mar 31, 2026 | 11.70 Mn |
| Dec 31, 2025 | 15.15 Mn |
| Sep 30, 2025 | 15.68 Mn |
| Jun 30, 2025 | 15.53 Mn |
| Mar 31, 2025 | 10.68 Mn |
| Dec 31, 2024 | 14.97 Mn |
| Sep 30, 2024 | 14.12 Mn |
| Jun 30, 2024 | 11.84 Mn |
| Mar 31, 2024 | 15.98 Mn |
| Dec 31, 2023 | 16.42 Mn |
| Sep 30, 2023 | 12.88 Mn |
| Jun 30, 2023 | 12.37 Mn |
| Mar 31, 2023 | 13.65 Mn |
| Dec 31, 2022 | 13.86 Mn |
| Sep 30, 2022 | 11.21 Mn |
| Jun 30, 2022 | 9.26 Mn |
| Mar 31, 2022 | 6.27 Mn |
| Dec 31, 2021 | 6.01 Mn |
| Sep 30, 2021 | 5.82 Mn |